Diabetes drugs are divided into oral hypoglycemic drugs and injectable preparations. At present, there are seven types of oral hypoglycemic drugs as follows: a. biguanides, mainly metformin, mainly through the inhibition of hepatic glucose output, glucose-lowering effect, is the first choice of drugs for type 2 diabetes and the basis of the combination of drugs; b. glinides, such as Repaglinide, nateglinide; c. sulfonylureas, such as gliclazide, glipizide, glimepiride, glipizide, glipizide, etc., both of which are through the promotion of insulin secretion These two types of drugs promote insulin secretion to lower glucose and are prone to hypoglycemia; fourth, thiazolidinediones, such as rosiglitazone and pioglitazone, mainly increase the sensitivity of target tissues to insulin; fifth, alpha glucosidase inhibitors, such as acarbose and voglibose, inhibit alpha glucosidase to delay carbohydrate absorption and lower postprandial blood glucose; sixth, dipeptidyl peptidase-IV inhibitors, such as saxagliptin, alogliptin and selegiline. vii. Dipeptidyl peptidase-IV inhibitors, such as saxagliptin, alogliptin, selegiline, and viligliptin, mainly act by increasing endogenous GLP-1 levels; vii. Sodium-glucose cotransporter 2 inhibitors, such as daglitazone and engramliptin, mainly act by promoting renal excretion of glucose. Injectable agents for diabetes include insulin and glucagon-like peptide-1 receptor agonists.